Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Covance and M2Gen® Enter into Alliance

Published: Friday, March 01, 2013
Last Updated: Friday, March 01, 2013
Bookmark and Share
Combines Covance’s comprehensive drug development capabilities with M2Gen’s innovative cancer-focused data warehouse to help accelerate development of targeted therapies for cancer patients.

Covance Inc. has announced that it has entered into an exclusive alliance and services agreement with M2Gen, a subsidiary of the Moffitt Cancer Center and leader in advancing personalized medicine by using high-quality tissue, clinical data and molecular technology to advance research for personalized cancer treatments.

Under the agreement, Covance and M2Gen will work together to offer biopharmaceutical clients the ability to match potential patients for biomarker-driven oncology trials with the right treatment or clinical trial.

In addition, Covance will become the preferred provider for M2Gen for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be conducted at Covance’s genomics laboratory in Seattle, Washington.

M2Gen’s cancer-focused data warehouse, one of the largest of its kind in the world, and related specimen biorepository, links longitudinal clinical, molecular and specimen data from more than 95,000 consented patients from Moffitt Cancer Center and a consortium of 17 hospitals throughout the United States.

M2Gen uses a proprietary healthcare informatics platform to support a clinical trial matching program, which can significantly reduce the timeline for identifying suitable participants for enrollment in clinical trials and improve the design of biomarker driven trials.

"Working together, Covance and M2Gen expect to help biopharmaceutical companies accelerate their drug development programs, make better decisions, and improve their efforts to develop targeted therapies for cancer patients," said Ken Somberg, MD, Chief Medical Officer for Covance and Vice President, Clinical Development Services.

Somberg continued, "M2Gen’s database is unique in the industry, with clinical data captured and maintained over the cancer patient’s lifetime. This alliance will help us partner with sponsors as the field of personalized medicine continues to evolve, and as we work toward a common goal of bringing new life-saving medicines to patients who need them.”

“M2Gen considers Covance to be an ideal strategic partner with the goal of connecting patients to the best treatment options, including clinical trials, by accelerating the discovery and delivery of personalized medicine,” said Bill Dalton, PhD, MD, President and CEO of M2Gen.

Covance is a leader in clinical oncology and has conducted more than 130 trials across several tumor types in the past five years on behalf of biopharmaceutical sponsors.

The alliance with M2Gen will extend Covance’s personalized medicine strategy and reinforce its drug development capabilities in this key therapeutic area.

M2Gen and Moffitt Cancer Center will continue efforts to add new hospitals to their network, further expanding access to clinical data for thousands of consenting cancer patients across the United States.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!